Genitourinary Cancers Symposium (ASCO GU) | Conference

Lenvatinib Plus Everolimus Safe, Effective Following Immunotherapy in Clear Cell RCC

February 11th 2021

February 11, 2021 - Lenvatinib in combination with everolimus has proven to be safe and effective when used in the treatment of patients with clear cell renal cell carcinoma who had previously received an immune checkpoint inhibitor.

Dr. Choudhury on the Rationale Behind Adding Pembrolizumab to Radium-223 in mCRPC

February 11th 2021

Atish D. Choudhury, MD, PhD, discusses the rationale behind combining pembrolizumab with radium-223 in patients with metastatic castration-resistant prostate cancer as part of a phase 2 clinical trial.

GU Experts Share Key Takeaways From 2020 Genitourinary Cancers Symposium

March 16th 2020

Key opinion leaders in the field share what they considered to be the greatest takeaways from the 2020 Genitourinary Cancers Symposium and provide insight on where treatment is headed in their respective areas of expertise.

Agarwal Shares Insight on Promise With Cabozantinib/Atezolizumab in mCRPC

February 25th 2020

Neeraj Agarwal, MD, discusses the COSMIC-021 trial and shares the next steps for this research.

Pal Highlights Encouraging ORR With Cabozantinib Plus Atezolizumab in mCRPC

February 24th 2020

Sumanta K. Pal, MD, discusses the cohort 6 findings of the COSMIC-021 trial and other key data that were presented during the 2020 Genitourinary Cancers Symposium.

Cabozantinib Plus Atezolizumab Active in mCRPC

February 19th 2020

The combination of cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Nivolumab/SBRT Data Leave Role of Radiation Unclear in RCC

February 17th 2020

Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma; however, the combination did not meet the primary endpoint of overall response rate.

Nivolumab Plus Sitravatinib Highly Active in ccRCC

February 17th 2020

Combining nivolumab (Opdivo) with sitravatinib induced a confirmed objective response rate of 39% and a 92% clinical benefit rate in patients with advanced clear cell renal cell carcinoma.

Novel Agent MK-6482 Shows Promise in Renal Cell Carcinoma

February 16th 2020

The oral hypoxia-inducible factor-2α inhibitor MK-6482 induced a partial response rate of 24% and a disease control rate of 80% in patients with advanced clear cell renal cell carcinoma.

Nivolumab Neoadjuvant Regimen Nears 50% pCR in MIBC

February 16th 2020

The neoadjuvant regimen of nivolumab combined with gemcitabine and cisplatin achieved a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49% in patients with muscle-invasive bladder cancer.

Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer

February 15th 2020

A neoadjuvant regimen of durvalumab plus olaparib induced a pathologic complete response rate of 50% in patients with muscle-invasive bladder carcinoma.

Dr. Antonarakis on Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

February 15th 2020

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Choueiri on Phase I/II Data of MK-6482 in Advanced Clear Cell RCC

February 15th 2020

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Radium-223 Plus Sipuleucel-T Yields Mixed Results in mCRPC

February 14th 2020

Combination therapy with radium-223 and sipuleucel-T yielded conflicting results in patients with metastatic castration-resistant prostate cancer.

Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy

February 14th 2020

Adding apalutamide to androgen deprivation therapy reduced the risk of second progression or death by 34% compared with ADT alone in patients with metastatic castration-sensitive prostate cancer.

Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC

February 14th 2020

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.

Dr. Gupta on BLASST-1 Results in Muscle-Invasive Bladder Cancer

February 13th 2020

Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the results of the phase II BLASST-1 trial, which is evaluating nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer who are undergoing cystectomy.

Frontline Enfortumab Vedotin Plus Pembrolizumab Shows Encouraging Data in Advanced Urothelial Cancer

February 11th 2020

Enfortumab vedotin-ejfv combined with pembrolizumab led to an objective response rate of 73% in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-based chemotherapy.

Cabozantinib Shows Strength After Immunotherapy in Renal Cell Carcinoma

February 10th 2020

Cabozantinib demonstrated impressive progression free survival when administered post-immunotherapy in patients with metastatic renal cell carcinoma.

Bempegaldesleukin/Nivolumab Combo May Address Unmet Need in Metastatic Urothelial Carcinoma

February 18th 2019

Arlene O. Siefker-Radtke, MD, discusses the promising preliminary data with bempegaldesleukin plus nivolumab in patients with metastatic urothelial carcinoma and the next steps for this combination.